Pet amiloide en la esclerosis múltiple

  1. Pytel, Vanesa
Zuzendaria:
  1. Jorge Matías-Guiu Guía Zuzendaria
  2. Jordi A. Matías-Guiu Zuzendaria
  3. María Nieves Cabrera Martín Zuzendaria

Defentsa unibertsitatea: Universidad Complutense de Madrid

Fecha de defensa: 2019(e)ko iraila-(a)k 30

Epaimahaia:
  1. José Luis Carreras Delgado Presidentea
  2. Francisco Grandas Pérez Idazkaria
  3. Alfredo Rodríguez-Antigüedad Zarranz Kidea
  4. Mª Rosario Blasco Quílez Kidea
  5. Julián Benito León Kidea

Mota: Tesia

Laburpena

Multiple sclerosis (MS) is the most common demyelinating disease and the main cause of non-traumatic neurological disability in young adults. It is a clinically heterogeneous disease, including motor, cognitive and fatigue symptoms. This is the result of a combination of the main pathophysiological processes involved: inflammation, demyelination, axonal damage and neurodegeneration. In recent years, various disease-modifying therapies have been developed, aimed at acting on the immune system, with an anti-inflammatory effect that prevents relapses and slows the progression of disability...